Despite the dedication of great efforts from the scientific community in developing small molecules with antagonistic effect on PRLR, and based on the key role of this receptor in leukemogenesis, designing novel therapeutic strategies to specifically disrupt the PRLR-mediated signaling in leukemic cells might provide a promising approach to overcome relapse and refractory episodes in AML. Here, PRLR is linked to acute myeloid leukemia.